Consistent with theclinical features, our results showed that patients with the CHST15 mutation exhibited an increased JAK2V617F allele burden and activated p-stat3 signaling, suggesting that the CHST15 mutation cooperateswith the classical JAK2 V617F mutation to trigger the MPN phenotype. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.